PT - JOURNAL ARTICLE AU - Alexander, Lori ED - Mehilli, Julinda TI - Bavarian Reperfusion Alternatives Evaluation-3 Trial DP - 2008 Jun 01 TA - MD Conference Express PG - 9--10 VI - 8 IP - 2 4099 - http://mdc.sagepub.com/content/8/2/9.2.short 4100 - http://mdc.sagepub.com/content/8/2/9.2.full AB - For patients with acute ST-elevation myocardial infarction (STEMI) who undergo primary coronary intervention, the addition of abciximab does not enhance the clinical benefits that are provided by pretreatment with high-dose clopidogrel, according to the findings of the Bavarian Reperfusion Alternatives Evaluation-3 [BRAVE-3] trial. Moreover, abciximab increases the risk of adverse clinical outcomes, suggesting that it should not be added to standard antiplatelet therapy in this patient population.